HC Wainwright Has Optimistic Outlook of ALDX FY2030 Earnings

Posted by Francis Steltz on Aug 18th, 2026

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX – Free Report) – Research analysts at HC Wainwright increased their FY2030 earnings per share (EPS) estimates for Aldeyra Therapeutics in a report issued on Monday, August 17th. HC Wainwright analyst M. Caufield now anticipates that the biotechnology company will post earnings of $0.36 per share for the year, up from their prior forecast of $0.34. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.43) per share.

Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09).

A number of other research analysts also recently commented on ALDX. Wall Street Zen downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings cut Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 20th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.50.

Get Our Latest Report on Aldeyra Therapeutics

Aldeyra Therapeutics Stock Performance

Shares of NASDAQ ALDX opened at $1.56 on Tuesday. The company has a market cap of $94.11 million, a price-to-earnings ratio of -4.00 and a beta of 1.22. Aldeyra Therapeutics has a 12-month low of $1.07 and a 12-month high of $6.17. The stock’s 50 day simple moving average is $1.80 and its 200 day simple moving average is $2.56.

Insider Activity at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, CEO Todd C. Brady purchased 250,000 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were bought at an average price of $1.67 per share, with a total value of $417,500.00. Following the completion of the acquisition, the chief executive officer owned 1,721,298 shares in the company, valued at approximately $2,874,567.66. This represents a 16.99% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 11.80% of the company’s stock.

Hedge Funds Weigh In On Aldeyra Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Global Retirement Partners LLC bought a new stake in Aldeyra Therapeutics during the 4th quarter valued at $52,000. CIBC Private Wealth Group LLC bought a new stake in shares of Aldeyra Therapeutics during the third quarter valued at about $55,000. BNP Paribas Financial Markets raised its stake in shares of Aldeyra Therapeutics by 36.9% during the third quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 2,859 shares in the last quarter. Federation des caisses Desjardins du Quebec lifted its holdings in Aldeyra Therapeutics by 25.8% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 12,187 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 2,500 shares during the period. Finally, Caption Management LLC lifted its holdings in Aldeyra Therapeutics by 110.6% in the second quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 132,358 shares during the period. 59.71% of the stock is owned by institutional investors.

About Aldeyra Therapeutics

(Get Free Report)

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.